The Directory of Pharma Companies and News


Immunocore is one of the world’s leading biotechnology companies, with a highlyinnovative immuno-oncology platform technology called ImmTACs. ImmTACs are anovel class of biologic drugs based on the Company’s proprietary T cell receptor (TCR)technology which have the potential to treat diseases with high unmet medical needincluding cancer, viral infections and autoimmune diseases. Immunocore, based on 3decades of world-leading scientific innovation in the discovery of HLA targets and T cellreceptor technology, has a pipeline of wholly-owned and partnered ImmTACprogrammes with robust clinical data, validated by collaborations with world-leadingpharmaceutical companies. Immunocore aims to leverage the utility of its platformacross a wide range of indications to become a Premier Biotech company and worldleaderin its field.Immunocore’s world-leading science and strong IP position has attracted majorpharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, thebiologics division of AstraZeneca, via discovery collaborations, as well as a co-discoveryand co-development partnership with Lilly. The Company has also entered intocombination trials with its lead programme, IMCgp100 in melanoma, with Medimmuneand Lilly. Founded in 2008 originally out of Oxford University and headquarteredoutside Oxford, Immunocore now has more than 155 staff. Immunocore is well fundedand owned by a group of international private, institutional and strategic investors.

Innunocore News

2016-03-30Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
2016-01-25Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
2016-01-20Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab
2016-01-06Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration
2015-12-17Immunocore expands its senior management team and opens US Office
2015-12-03Immunocore wins Biotech of the Year at the SCRIP Awards 2015
2015-09-09Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme
2015-09-07Immunocore Ranked No 1 South East Company in the Annual Sunday Times Hiscox Tech Track 100
2015-08-06The Royal Society publishes a video case study on Immunocore
2015-07-29Immunocore announces Fidelity’s Participation in $320M Financing
2015-07-16Immunocore secures $320 million (£205 million) in Europe’s Largest Private Life Sciences Financing
2015-07-09Chief Executive Eliot Forster’s interview with Consilium Strategic Communications
2015-06-29Immunocore and Lilly announce immunotherapy-based clinical trial collaboration in melanoma
2015-06-12Immunocore Wins Emerging Star of the Year Award at the European Mediscience Awards 2015
2015-05-28Dr. Bent Jakobsen, Immunocore’s Chief Scientific Officer, elected to the Fellowship of the Academy of Medical Sciences
2015-05-11Immunocore to attend Citi European Healthcare Conference 2015 and BioTrinity 2015
2015-04-20Immunocore Announces Positive Clinical Trial Data for Novel First-in-Class Immunotherapy at AACR Annual Meeting 2015
2015-04-16Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
2015-04-08Immunocore to Present IMCgp100 Clinical Trial Data at AACR Annual Meeting 2015
2015-04-01Immunocore appoints Dr. Christina Coughlin as Chief Medical Officer
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.